Cancer-associated fibroblast stimulates cancer cell invasion in an interleukin-1 receptor (IL-1R)-dependent manner by �옣�뼢��
ONCOLOGY LETTERS  18:  4645-4650,  2019
Abstract. Tumor microenvironment serves an important 
role in tumor growth and metastasis. Cancer cells can 
promote growth and malignancy by altering the surrounding 
stroma. Cancer‑associated fibroblast (CAF) are an abundant 
cell type present within the tumor microenvironment and 
provide tumorigenic features by secreting cytokines. In the 
current study, the CAF‑mediated invasion of oral squamous 
cell carcinoma (OSCC) was investigated and the associated 
mechanisms were elucidated. Cancer invasion was estimated 
using a Matrigel‑coated Transwell chamber and FITC‑gelatin 
matrix. To verify the effect of the tumor microenvironment, 
conditioned media (CM) from normal fibroblast (NF) and 
CAFs were prepared. An ELISA was performed to estimate 
the level of IL-1β. A proteome profiler human protease array 
was performed to verify the proteases affected by stimulation 
with CM, from CAF. Recombinant IL‑1β protein increased the 
invasion of OSCC cells. IL-1β expression was higher in CAF 
than NF. CM from CAF (CM‑CAF) increased cancer invasion 
and FITC‑gelatin matrix degradation. The invasive capacity 
provided by CAF was abrogated by an IL‑1 receptor (IL‑1R) 
antagonist. Additionally, CM‑CAF increased the secretion of 
ADAM 9 and Kallikrein 11 from OSCC cells. The invasion 
activity by CM‑CAF was partially abrogated by the neutraliza-
tion of ADAM 9 or Kallikrein 11. In conclusion, by providing 
stromal factor, CAFs were a critical inducer of OSCC inva-
sion, and CAF secretes the required amount of IL‑1β to 
increase cancer invasion activity. The invasive capacity of 
CAF was identified to be IL‑1R‑dependent. ADAM 9 and 
Kallikrein 11 were influencing factors involved in the increase 
of CAF‑mediated cancer invasion.
Introduction
The tumor microenvironment is closely related to cancer 
initiation, progression, and invasion (1). The tumor 
microenvironment consists of extracellular matr ix 
(ECM), stromal cells (such as fibroblasts, myofibroblasts, 
neuroendocrine cells, adipose cells, immune and inflammatory 
cells, blood, and lymphatic vascular networks) and immune 
cells (including T and B lymphocytes, natural killer cells, 
and tumor‑associated macrophages), however, the precise 
function of each constituent remains unknown (2). Tumor 
initiation proceeds with a complex series of biological changes 
whereby normal cells acquire uncontrolled cell growth and 
resistance to cell death. In conditions of hypoxia, oxidative 
stress, and acidosis, the tumor microenvironment alters 
cellular metabolism and leads to the subsequent evolution of 
malignancies. The overexpression of oncogenes during tumor 
growth and progression by stromal stimuli can affect the 
aggressiveness of cancer. Cancer‑associated fibroblasts (CAFs) 
were shown to promote tumor growth and the invasion of 
low‑invasive cancer cells in xenografted mice (3). Therefore, 
a complex tissue microenvironment is necessary for tumor 
progression and metastasis (4,5). Research on the tumor 
microenvironment is important to identify therapeutic targets 
and for the diagnosis of cancer.
Cancer cells that have acquired the ability to invade 
infiltrate nearby healthy tissues and spread beyond the tissue 
layer. Reports that many kinds of cytokines and chemokines 
were involved in every stage of tumorigenesis have suggested 
that reciprocal cross-talk between cancer and adjacent 
stroma is important for cancer progression (6). The role of 
platelet‑derived growth factor (PDGF), fibroblast activation 
protein (FAP), fibroblast growth factor receptor (FGFR), 
vitamin D receptor (VDR), transforming growth factor‑β 
(TGF‑β), tumor necrosis factor‑α (TNF‑α), interleukin‑10 
(IL‑10), interleukin‑12 (IL‑12), epidermal growth factor 
(EGF), and vascular endothelial growth factor (VEGF) have 
been suggested as critical tumor microenvironment factors for 
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tumor progression (1). In addition, matrix metalloprotease‑2 
(MMP‑2) from cancer‑associated fibroblasts has been reported 
to induce epithelial invasion and dis-cohesion of keratinocytes 
into collagen (7). Therefore, analysis of cross‑talk between 
cancer and CAF is important in understanding the mechanism 
of cancer invasion.
In this study, we observed the role of CAFs in cancer inva-
sion as tumor microenvironment and elucidated the related 
mechanism. Our results demonstrated that CAFs were critical 
inducers of OSCC invasion and that their invasive capacity 
was IL‑1R‑dependent. CAF stimulation results in an increase 
in protease, such as ADAM 9 and Kallikrein 11. The results of 
this study may be useful in helping to identify the role of CAFs 
in cancer invasion and progression and to generate therapeutic 
strategies for treating cancers.
Materials and methods
Cell culture. HSC‑2 oral squamous cell carcinoma (OSCC) 
cells was grown in DMEM/F12 (3:1 ratio) medium supple-
mented with 10% FBS, 1x10-10 M cholera toxin, 0.4 mg/ml 
hydrocortisone, 5 µg/ml insulin, 5 µg/ml apo‑transferrin, and 
2x10-11 M triiodothronine (T3) in a humidified atmosphere 
of 5% CO2 at 37˚C. Normal gingival fibroblasts (NF) and 
cancer‑associated fibroblasts (CAF) were maintained in 
complete medium as for HSC‑2 cells. Early passage (below 
passage 10) of the fibroblasts were subjected to analysis.
Reagents. All reagents used in cell culture were purchased 
from Gibco BRL Co. (Rockville, MD, USA). Cholera toxin, 
hydrocortisone, insulin, apo‑transferrin, T3, and dimethyl 
sulfoxide (DMSO) were obtained from Sigma Chemical Co. 
(St. Louis, MO, USA). Recombinant human interleukin 1 beta 
(IL‑1β) was purchased from R&D Systems (Minneapolis, 
MN, USA). IL‑1R antagonist was purchased from Cayman 
(Cayman Chemical, Ann Arbor, MI, USA). GM6001 was 
purchased from Calbiochem (La Jolla, CA, USA). Oregon 
Green 488 gelatin were purchased from Molecular Probes 
(Carlsbad, CA, USA).
Invasion assay. 8 µm pore sized polycarbonate nucleopore 
filter inserts in a 24‑well Transwell chamber (Corning 
Costar, Cambridge, MA, USA) were coated with Matrigel 
(30 mg/well; Becton Dickinson, Lincoln Park, NJ, USA) for 
4 h. Cells (5x104 cells) were added into the upper chamber, 
and complete medium was added to the bottom chamber and 
keep for 48 h at 37˚C incubator. Invaded cells on the lower 
surface of the Transwell membrane was fixed with absolute 
ethanol and noninvasive cells were removed with a cotton 
swab. Then invaded cells were stained with hematoxylin. Cells 
from five fields were counted under a microscope. The neutral-
izing effect of anti‑ADAM 9 antibody and anti‑Kallikrein 11 
antibody on the invasion activity of CM‑CAF was determined 
by incubating the cells with CM‑CAF after CM‑CAF were 
treated for 1 h with 1 mg/ml antibody to ADAM 9 (Abcam, 
Cambridge, MA, USA) and anti‑Kallikrein 11 (R&D Systems, 
Saint Louis, MO, USA).
Immunostaining. The xenograft tumor tissue was used 
to observe the expression of IL-1β. Tumor xenograft was 
established by implatation of OSCC cells in athymic nude 
mouse in our previous study (8). Briefly, OSCC cells were 
injected into mouse tongue and growth of tumor xenografts 
was observed for 5 weeks. Tissues were fixed in formalin and 
processed for paraffin embedding. Deparaffinized tissue were 
then rehydrated and conducted antigen retrieval via autoclave 
treatment of the sections in 0.01 M citrate buffer (pH 6.0). 
After blocking with 10% normal goat serum, the sections 
were incubated with a primary antibody at a 1:100 dilution 
in background reducing diluent (Dako, Carpinteria, CA, 
USA). The sections were rinsed with PBS and incubated with 
biotinylated anti‑mouse/anti‑rabbit IgG (H + L) (1:100 dilution 
in background reducing diluent), followed exposure to horse-
radish peroxidase streptavidin (1:200 dilution in background 
reducing diluent). Staining was performed by incubating 
with 3,3'‑diaminobenzidine (DAB) buffer. The sections were 
counterstained with hematoxylin, followed by dehydration and 
mounting.
Enzyme‑linked immunosorbent assay (ELISA). The cultured 
medium from NF and CAF were used as conditioned medium 
(CM). Media were then centrifuged, and the IL‑1β level was 
quantified with the Human IL‑1β Quantikine ELISA kit 
according to the manufacturer's protocols (R&D System Inc., 
Minneapolis, MN, USA).
ECM degradation. Oregon Green 488 gelatin-coated coverslips 
were prepared as described previously (9). Cells (3x103 cells) 
were plated on coverslips in 12-well plates and cultured for 
16 h. Cells were fixed with 4% paraformaldehyde followed by 
permeabilization with 0.5% Triton X‑100/PBS and stained for 
nuclei with DAPI. Areas of matrix degradation was identified 
by a loss fluorescence using an EVOS FL monochrome micro-
scope (ThermoFisher Scientific, Waltham, MA, USA).
Protease array. Cells were cultured in 1% medium with or 
without IL-1β and harvested after 24 h. Harvested medium was 
centrifuged in 5,000 rpm for 10 min and used as conditioned 
media (CM) for protease array. The protein concentration 
of the CM was normalized by dilution with serum‑free 
media. Then CM was incubated for 24 h with the Proteome 
Profiler Human Protease Array membrane (R&D Systems, 
Saint Louis, MO, USA). The relative expression levels of the 
proteases were determined according to the manufacturer's 
protocol and signal intensities were compared using ImageJ 
software program.
Statistical analysis. The statistical analysis was conducted 
using InStat™ statistical software (GraphPad Software, San 
Diego, CA, USA). The statistical significance of differences 
between groups was analyzed using a one‑way ANOVA with 
a Tukey's post‑hoc test. P‑values of <0.05 were considered 
significant.
Results
IL‑1β increases cancer cell invasion. To investigate the effect 
of IL-1β in cancer invasion, a Matrigel-coated Transwell inva-
sion assay was performed with 20 ng/ml IL‑1β for 48 hours. 
As shown in Fig. 1, recombinant IL‑1β treatment incresed 
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invasion 2.75‑fold compared to the control. To investigate the 
expression of IL-1β in the tumor, we used a xenofrafted tongue 
tumor specimen established in our previous experiments (8). 
IL-1β expression was located in the cytoplasm of the cancer 
cells and cancer‑associate fibroblasts. Relatively high IL‑1β 
expression was detected in the regional stroma (Fig. 2).
IL‑1β from CAFs increases matrix degradation. The level 
of IL-1β protein was measured in normal gingival fibro-
blasts (NFs) and cancer‑associated fibroblast (CAFs) using a 
Human IL‑1β Quantikine ELISA kit. As shown in Fig. 3A, 
IL-1β expression was 3.8‑fold higher in CAF than in NF. 
Conditioned medium (CM) from NF and CAF were used for 
Transwell invasion assay, instead of complete medium. Unlike 
NF, CAF increased cancer inasion by 2.1‑fold (Fig. 3B). The 
increased invasion activity by the CM of CAF (CM‑CAF) was 
abolished by an IL‑1R antagonist. Subsequently, we observed 
whether the invasion activity of cancer cells increased by 
CM‑CAF increased matrix degradation. Cancer cells were 
cultured for 16 h on FITC‑gelatin‑coated coverslips. CM‑CAF 
stimulation increased the degradation activity of FITC‑gelatin 
matrix compared to the control without CM‑CAF (Fig. 3C). 
The increased matrix degradation by CM‑CAF stimulation 
was abolished by IL-1R antagonist treatment. These results 
indicate that CM‑CAF increased proteolytic cancer invasion 
in an IL-1R-dependent manner.
IL‑1β increases the protease release. In order to explore the 
proteases that increased cancer invasion by CM‑CAF, the 
cells were stimulated with CM‑CAF and culture medium 
was analyzed using the Proteome Profiler Human Protease 
Array. Compared to control, the secretion of ADAM 9 and 
Kallikrein 11 was significantly increased by CM‑CAF treat-
ment. ADAM 9 and Kallikrein 11 were increased 4.21‑ and 
2.48‑fold, respectively (P<.01) (Fig. 4). The increased in 
Transwell invasion by CM‑CAF was partially abrogated by 
the neutralization of ADAM 9 or Kallikrein 11 (Fig. 5).
Discussion
Protease secretion by cancer cells is a pivotal process in 
cancer invasion and metastasis. Invasive cancer cells form a 
protrusive cellular structure, termed invadopodia, for effective 
cancer invasion, leading to the focal secretion of proteases into 
the nearby extracellular matrix (ECM) (10,11). Growth factors, 
such as colony stimulating factor‑1 (CSF‑1), TGF‑β, VEGF, 
PDGF, EGF, heparin‑binding EGF (HB‑EGF), hepatocyte 
growth factor/scatter factor (HGF), and stromal cell‑derived 
factor 1α (SDF1α) stimulate invadopodia formation (10). 
MMPs, ADAM (a disintegrin and metalloproteinase), shed-
dases, cysteine cathepsin proteases, and serine proteases are 
localized at invadopodia (12,13). TGF‑β and EGF are synthe-
sized in active proforms that are processed by MMPs and 
another protease into active and soluble ligands, suggesting a 
possible role for protease in invadopodia formation (10,14).
In the present study, IL-1β concentration was measured in 
normal fibroblast (NF) and cancer‑associated fibroblast (CAF), 
and higher IL-1β levels were observed in the CAF compared to 
the NF. Recombinant IL‑1β significantly increased cancer cell 
invasion on Matrigel‑coated Transwell chamber. Further, we 
investigated whether stromal fibroblasts could control cancer 
invasion. Conditioned media (CM) from NF and CAF were 
prepared and used as cultured media in Transwell chamber for 
invasion assay. Unlike CM from NF, CM from CAF (CM‑CAF) 
increased cancer cell invasion by increasing protease release. 
The invasive capacity provided by CM‑CAF was suppressed 
by an IL‑1 receptor (IL‑1R) antagonist. These results indi-
cate that the level of IL-1β in CM‑CAF was high enough 
to stimulate cancer invasion activity and that the increased 
invasion activity of the cancer cells resulting from CM‑CAF 
treatment was sustained by an IL-1R-dependent pathway. 
IL-1β is a pro‑inflammatory cytokine and its expression in 
primary tumors has been identified as a potential biomarker 
in cancer patients at increased risk for developing bone metas-
tasis (15). IL‑1 has been suggested as a critical molecule for 
tumor invasiveness and angiogenesis (16). Local tumors and 
lung metastases of B16 melanoma cells were abolished in IL‑1 
Figure 1. Cancer invasion by IL‑1β stimulation. Matrigel-coated transwell 
invasion was performed with or without recombinant IL-1β protein. An 
invasion assay was performed for 48 h. Cell invasion was detected by hema-
toxylin staining and counted. Representative results of the transwell invasion 
assay are shown. *P<0.01 vs. no IL‑1β stimulation. IL, interleukin.
Figure 2. Expression of IL‑1β in tumor xenograft. Representative immunohis-
tochemical staining images of IL-1β on xenografted tongue tumor specimen 
(original magnification, x100). Scale bar indicates 50 µm. IL, interleukin; T, 
tumor; S, stroma.
ZHANG  and  HWANG:  CANCER‑ASSOCIATED FIBROBLAST STIMULATES CANCER CELL INVASION4648
knockout (KO) mice. IL‑1β secreted by OSCC cells recipro-
cally stimulated secretion of transforming growth factor beta 1 
(TGF‑β1) from stromal fibroblasts, thereby leading to cancer 
invasion by increasing podoplanin (PDPN) expression, one of 
the components of invadopodia (17). These results indicate that 
cancer invasion is regulated by reciprocal cross-talk between 
cancer and the regional microenvironment. Thus, the influence 
of the tumor microenvironment is important in elucidating the 
mechanism of cancer invasion. According to a recent report, 
cancer‑associated fibroblasts also formed invadopodia, thereby 
promoting invasion activity of pancreatic cancer cells (18).
The stroma consists of the basement membrane, fibro-
blasts, extracellular matrix, immune cells, and vascular system 
and plays a structural and connective role in tissues. Normal 
stroma maintains homeostasis by inhibiting inflammation and 
neoplasia through immune systems functions. However, in the 
tumor environment, it plays a role in promoting cancer growth 
and malignant tumors (19). Cancer‑associated fibroblasts 
(CAFs) are abundant cells within the tumor microenvironment 
and promote tumorigenic features by initiating remodeling 
of the extracellular matrix (ECM) and secreting cytokines. 
CAFs are continuously activated and lack the ablility to revert 
into a normal phenotype or undergo apoptosis, resulting in a 
constant number of CAFs. (19). Consequently, the reciprocal 
cross-talk between stromal tissue and tumor plays a pivotal 
role in cancer growth and progression (20). We previously 
demonstrated that CAFs promoted tumor growth in athymic 
nude mice (3). Tumor growth was significantly increased 
Figure 3. Effect of CAF on cancer invasion activity. (A) The levels of IL‑1β in NF and CAF were measured using a Human IL‑1β Quantikine ELISA kit. 
*P<0.01 vs. NF. (B) Effect of CM from NF and CAF on cancer invasion was estimated with or without IL‑1 receptor (IL‑1R) antagonist. *P<0.01 vs. none, 
#P<0.01 vs. without IL‑1R antagonist in CAF. (C) Extracellular matrix degradation activity of cancer cells by CM from CAF (CM‑CAF). Cells were cultured 
on Oregon Green 488 gelatin‑coated coverslips and areas of matrix degradation were identified by a loss fluorescence using an EVOS FL monochrome micro-
scope (original magnification, x100). IL‑1(R) antagonist; IL‑1 receptor antagonist. CAF, cancer‑associated fibroblast; IL, interleukin; NF, normal fibroblast; 
CM, conditioned media.
Figure 4. Effect of CM from CAF (CM‑CAF) stimulation on proteases release from oral squamous cell carcinoma cells. CM‑CAF was incubated with Protease 
Array membrane and relative signal intensities were determined using ImageJ software program. Proteases with large signal changes are indicated by circled 
numbers. *P<0.001 vs. none. CM, conditioned media; CAF, cancer‑associated fibroblast.
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in xenograft mixtures of CAF and cancer cell compared to 
xenografts of cancer cell only in a 5-weeks experiment. This 
result indicates that the existence of molecular cross-talk 
between cancer cells and surrounding stroma is important for 
enhancing tumor growth. Thus, targeting of CAFs is important 
for understanding cancer invasion and finding keys to suppress 
cancer progression. However, there is little research on the role 
of IL-1β in CAF‑mediated stimulation of cancer invasion. In 
this study, we demonstrated that CM‑CAF contained signifi-
cant amounts of IL-1β and induced the secretion of proteases 
from OSCC cells.
In the present study, CM‑CAF was shown to stimulate 
the enhanced secretion of ADAM 9 (MDC9, meltrin β) and 
Kallikrein 11 (KLK11, TLSP, PRSS20) from OSCC cells. 
The increased Transwell invasion by CM‑CAF was abrogated 
by neutralization of ADAM 9 or Kallikrein 11. ADAM 9 is 
known as metalloprotease disintegrin cysteine-rich protein 9 
or meltrin β. Overexpression of ADAM 9 has been identified 
in a variety of cancer types, including breast cancer, renal 
cancer, prostate cancer, skin cancer, uterine cervical cancer, 
hepatocellular carcinoma, non-small cell lung cancer, colon 
cancer, gastric cancer, esophageal cancer, and head and neck 
squamous cell carcinoma (HNSCC) (21). ADAM 9 is induced 
by oxidative stress, such as intracellular reactive oxygen 
species (ROS) and/or hydrogen peroxide, thereby supporting 
prostate cancer cell survival and progression (22). Enhanced 
ADAM 9 expression has been reported in oral squamous cell 
carcinoma (OSCC) compared to normal oral tissue. Moreover, 
a high degree of ADAM 9 expression has been observed in 
well‑differentiated OSCC (21). Kallikrein 11 (KLK11) is a 
secreted type of serine protease, highly expressed in many 
tissues including brain, skin, salivary gland, stomach, pros-
tate, and intestine (23). KLK11 expression holds prognostic 
significance in prostate cancer (24). In vivo studies have 
demonstrated that overexpression of KLK11 led to tumor 
progression and metastasis of prostate cancer. Overexpression 
of KLK11 in ER(+) breast cancer cells led to breast cancer 
progression by increasing the bioavailability of IGFs via degra-
dation of insulin‑like growth factor (IGF) binding protein 3 
(IGFBP‑3) (25). Previously, KLK11 has been proposed as a 
diagnostic biomarker of prostate and ovarian carcinoma (26). 
IL-1β increased the expression of an ADAM 9 in hepatocel-
lular carcinoma (HCC) cell to escape from the host immune 
surveillance (27). The relation between IL‑1β and KLK11 
has not been reported. Neutralization of IL‑1 receptor (IL‑R) 
will be a useful tool in elucidating the mechanisms involved 
in IL-1β‑induced ADAM 9 or KLK11 production. The role 
of ADAM 9 and KLK11 induced by CM‑CAF in OSCC cell 
invasion also require further investigations. Identification 
of the cellular mechanism of protease controlled by stromal 
factor IL-1β would be of immense significance.
In conclusion, CAFs were observed to increase cancer inva-
sion in an IL‑1R‑dependent manner. The release of ADAM 9 
and Kallikrein 11 from OSCC cells was also stimulated by 
CAFs. A study on the molecular mechanism of CAF‑induced 
proteases secretion from cancer cells is needed to further 
investigate cancer invasion. Targeting the cancer microenvi-
ronment is important for cancer control.
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Figure 5. Effect of neutralization of ADAM 9 or Kallikrein 11 on Transwell 
invasion activity by CM‑CAF. CM‑CAF were treated with 1 mg/ml anti-
body to ADAM 9 or anti‑Kallikrein 11 for 1 h and were added to the lower 
chamber of Transwell plates. After incubation, the invaded cells were stained 
and counted. Results represent the mean ± standard error of three indepen-
dent experiments. *P<0.01 vs. CM‑CAF alone. CM, conditioned media; CAF, 
cancer‑associated fibroblast.
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